OD36
Code | Size | Price |
---|
TAR-T35694-1mg | 1mg | £213.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T35694-5mg | 5mg | £422.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T35694-10mg | 10mg | £589.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T35694-25mg | 25mg | £863.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T35694-50mg | 50mg | £1,179.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T35694-100mg | 100mg | £1,564.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Potent receptor-interacting protein kinase 2 (RIPK2) inhibitor (IC50 = 5.3 nM). Displays similar % inhibition against ALK-2 and SIK2 at 100 nM. Downregulates expression of a panel of RIPK2-dependent genes. Inhibits recruitment of inflammatory cells in a mouse MDP-induced peritonitis model.
CAS:
1638644-62-8
Formula:
C16H15ClN4O2.HCl
Molecular Weight:
367.23
Pathway:
Angiogenesis|NF-κb|Apoptosis|Tyrosine Kinase/Adaptors
Purity:
0.98
SMILES:
ClC1=CC(C2=C3N=C(NCCOCCO4)C=CN3N=C2)=CC4=C1.Cl
Target:
RIP kinase|ALK
References
Tigno-Aranjuez JT, et al. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J Biol Chem. 2014 Oct 24;289(43):29651-64.
Gonzalo S?nchez-Duffhues, et al. Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells. JBMR Plus. 2019 Oct 7;3(11):e10230.
Justine T Tigno-Aranjuez, et al. In vivo inhibition of RIPK2 kinase alleviates inflammatory disease. J Biol Chem. 2014 Oct 24;289(43):29651-64.